185 related articles for article (PubMed ID: 26656134)
21. Mutations in serine protease inhibitor Kazal type 1 are strongly associated with chronic pancreatitis.
Drenth JP; te Morsche R; Jansen JB
Gut; 2002 May; 50(5):687-92. PubMed ID: 11950817
[TBL] [Abstract][Full Text] [Related]
22. Cyst fluid SPINK1 may help to differentiate benign and potentially malignant cystic pancreatic lesions.
Räty S; Sand J; Laukkarinen J; Vasama K; Bassi C; Salvia R; Nordback I
Pancreatology; 2013; 13(5):530-3. PubMed ID: 24075519
[TBL] [Abstract][Full Text] [Related]
23. Human cationic trypsinogen but not serine peptidase inhibitor, Kazal type 1 variants increase the risk of type 1 autoimmune pancreatitis.
Chang MC; Jan IS; Liang PC; Jeng YM; Yang CY; Tien YW; Wong JM; Chang YT
J Gastroenterol Hepatol; 2014 Dec; 29(12):2038-42. PubMed ID: 24909264
[TBL] [Abstract][Full Text] [Related]
24. SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence.
Grupp K; Diebel F; Sirma H; Simon R; Breitmeyer K; Steurer S; Hube-Magg C; Prien K; Pham T; Weigand P; Michl U; Heinzer H; Kluth M; Minner S; Tsourlakis MC; Izbicki JR; Sauter G; Schlomm T; Wilczak W
Prostate; 2013 Nov; 73(15):1690-8. PubMed ID: 23843146
[TBL] [Abstract][Full Text] [Related]
25. Metastatic pancreatic adenocarcinoma associated with chronic calcific pancreatitis and a heterozygous SPINK1 N34S mutation.
Moran RA; Klapheke R; Jalaly NY; Makary MA; Hirose K; Goggins M; Wood L; Laheru DA; Lennon AM; Khashab MA; Singh VK
Pancreatology; 2016; 16(5):869-72. PubMed ID: 27358244
[TBL] [Abstract][Full Text] [Related]
26. Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy.
Rink M; Park K; Volkmer BG; Xylinas E; Hansen J; Cha EK; Robinson BD; Hautmann R; Küfer R; Engel O; Chun FK; Dahlem R; Rubin MA; Shariat SF; Mosquera JM
Urol Oncol; 2013 Nov; 31(8):1716-24. PubMed ID: 22944196
[TBL] [Abstract][Full Text] [Related]
27. CFTR, SPINK1, PRSS1, and CTRC mutations are not associated with pancreatic cancer in German patients.
Schubert S; Traub F; Brakensiek K; von Kopylow K; Marohn B; Maelzer M; Gaedcke J; Kreipe H; Stuhrmann M
Pancreas; 2014 Oct; 43(7):1078-82. PubMed ID: 25003218
[TBL] [Abstract][Full Text] [Related]
28. SPINK1 Status in Colorectal Cancer, Impact on Proliferation, and Role in Colitis-Associated Cancer.
Ida S; Ozaki N; Araki K; Hirashima K; Zaitsu Y; Taki K; Sakamoto Y; Miyamoto Y; Oki E; Morita M; Watanabe M; Maehara Y; Yamamura K; Baba H; Ohmuraya M
Mol Cancer Res; 2015 Jul; 13(7):1130-8. PubMed ID: 25804623
[TBL] [Abstract][Full Text] [Related]
29. An immunocapture-LC-MS-based assay for serum SPINK1 allows simultaneous quantification and detection of SPINK1 variants.
Ravela S; Valmu L; Domanskyy M; Koistinen H; Kylänpää L; Lindström O; Stenman J; Hämäläinen E; Stenman UH; Itkonen O
Anal Bioanal Chem; 2018 Feb; 410(6):1679-1688. PubMed ID: 29318362
[TBL] [Abstract][Full Text] [Related]
30. SPINK1, ADH2, and ALDH2 gene variants and alcoholic chronic pancreatitis in Japan.
Shimosegawa T; Kume K; Masamune A
J Gastroenterol Hepatol; 2008 Mar; 23 Suppl 1():S82-6. PubMed ID: 18336671
[TBL] [Abstract][Full Text] [Related]
31. Absence of PRSS1 mutations and association of SPINK1 trypsin inhibitor mutations in hereditary and non-hereditary chronic pancreatitis.
Chandak GR; Idris MM; Reddy DN; Mani KR; Bhaskar S; Rao GV; Singh L
Gut; 2004 May; 53(5):723-8. PubMed ID: 15082592
[TBL] [Abstract][Full Text] [Related]
32. Serine protease inhibitor Kazal type 1 promotes epithelial-mesenchymal transition through EGFR signaling pathway in prostate cancer.
Wang C; Wang L; Su B; Lu N; Song J; Yang X; Fu W; Tan W; Han B
Prostate; 2014 May; 74(7):689-701. PubMed ID: 24619958
[TBL] [Abstract][Full Text] [Related]
33. Application of proteomic technology in identifying pancreatic secretory trypsin inhibitor variants in urine of patients with pancreatitis.
Valmu L; Paju A; Lempinen M; Kemppainen E; Stenman UH
Clin Chem; 2006 Jan; 52(1):73-81. PubMed ID: 16254194
[TBL] [Abstract][Full Text] [Related]
34. SPINK1 mutations are associated with multiple phenotypes.
Pfützer RH; Whitcomb DC
Pancreatology; 2001; 1(5):457-60. PubMed ID: 12120224
[TBL] [Abstract][Full Text] [Related]
35. Serum tumour associated trypsin inhibitor, as a biomarker for survival in renal cell carcinoma.
Tornberg SV; Nisen H; Järvinen P; Järvinen R; Kilpeläinen TP; Taari K; Stenman UH; Visapää H
Scand J Urol; 2020 Oct; 54(5):413-419. PubMed ID: 32748674
[TBL] [Abstract][Full Text] [Related]
36. Serine Protease Inhibitor Kazal Type 1 (SPINK1) Promotes Proliferation of Colorectal Cancer Through the Epidermal Growth Factor as a Prognostic Marker.
Chen YT; Tsao SC; Yuan SS; Tsai HP; Chai CY
Pathol Oncol Res; 2015 Sep; 21(4):1201-8. PubMed ID: 26037168
[TBL] [Abstract][Full Text] [Related]
37. Pancreatic secretory trypsin inhibitor-like immunoreactivity in pancreatectomized patients.
Halila H; Huhtala ML; Schröder T; Kiviluoto T; Stenman UH
Clin Chim Acta; 1985 Dec; 153(3):209-16. PubMed ID: 3935345
[TBL] [Abstract][Full Text] [Related]
38. Pancreatic secretory trypsin inhibitor: More than a trypsin inhibitor.
Wang GP; Xu CS
World J Gastrointest Pathophysiol; 2010 Jun; 1(2):85-90. PubMed ID: 21607145
[TBL] [Abstract][Full Text] [Related]
39. Serine protease inhibitor Kazal type 1 mutations and pancreatitis.
Schneider A
Gastroenterol Clin North Am; 2004 Dec; 33(4):789-806. PubMed ID: 15528018
[TBL] [Abstract][Full Text] [Related]
40. The construction and proliferative effects of a lentiviral vector capable of stably overexpressing SPINK1 gene in human pancreatic cancer AsPC-1 cell line.
Zhang J; Wang D; Hu N; Wang Q; Yu S; Wang J
Tumour Biol; 2016 May; 37(5):5847-55. PubMed ID: 26586397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
